The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
specificity of MBI
We will compare the outcome of the biopsies with the determinations made with the MBI examinations. The rate of unnecessary biopsies will be determined by the specificity and prevalence of cancer in the dataset. Thus, we formulate our primary statistical hypothesis in terms of a reduction in the false positive frequency (namely an improvement in specificity) of the pre-biopsy diagnostic work-up that includes MBI.
1 year
No
Christiane Hakim, MD
Principal Investigator
University of Pittsburgh
United States: Institutional Review Board
PRO12030005
NCT01687790
September 2012
September 2014
Name | Location |
---|---|
Hillman Cancer Center | Pittsburg, Pennsylvania 15232 |